A detailed history of Parkman Healthcare Partners LLC transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Parkman Healthcare Partners LLC holds 178,335 shares of KROS stock, worth $8.15 Million. This represents 1.6% of its overall portfolio holdings.

Number of Shares
178,335
Previous 360,467 50.53%
Holding current value
$8.15 Million
Previous $14.3 Million 17.63%
% of portfolio
1.6%
Previous 2.06%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$41.26 - $70.48 $7.51 Million - $12.8 Million
-182,132 Reduced 50.53%
178,335 $11.8 Million
Q4 2023

Feb 14, 2024

BUY
$27.12 - $41.05 $1.68 Million - $2.54 Million
61,992 Added 20.77%
360,467 $14.3 Million
Q3 2023

Nov 14, 2023

BUY
$31.57 - $43.02 $683,806 - $931,813
21,660 Added 7.82%
298,475 $9.52 Million
Q2 2023

Aug 11, 2023

BUY
$37.26 - $51.01 $3.63 Million - $4.97 Million
97,525 Added 54.4%
276,815 $11.1 Million
Q1 2023

May 12, 2023

BUY
$41.44 - $59.32 $2.18 Million - $3.11 Million
52,500 Added 41.41%
179,290 $7.66 Million
Q4 2022

Feb 13, 2023

BUY
$39.45 - $51.77 $1.06 Million - $1.39 Million
26,863 Added 26.88%
126,790 $6.09 Million
Q3 2022

Nov 14, 2022

BUY
$27.8 - $40.12 $1.45 Million - $2.09 Million
52,139 Added 109.1%
99,927 $3.76 Million
Q2 2022

Aug 12, 2022

SELL
$26.03 - $67.04 $648,199 - $1.67 Million
-24,902 Reduced 34.26%
47,788 $1.32 Million
Q1 2022

May 13, 2022

BUY
$42.12 - $59.36 $119,157 - $167,929
2,829 Added 4.05%
72,690 $3.95 Million
Q4 2021

Feb 11, 2022

BUY
$36.95 - $62.89 $2.58 Million - $4.39 Million
69,861 New
69,861 $4.09 Million

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $1.18B
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Parkman Healthcare Partners LLC Portfolio

Follow Parkman Healthcare Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parkman Healthcare Partners LLC with notifications on news.